Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oral Amycretin (NNC0487-0111) in Japanese Participants with Obesity
NCT06049329Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amycretin in obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Number of Treatment Emergent Adverse Events. Started Sep 2023; status: completed.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06049329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049329.